The 'Omics' of Amyotrophic Lateral Sclerosis

Trends in Molecular Medicine

Volumn 22, Issue 1, 2016, Pages 53-67

  Caballero Hernandez, Diana ^a   Toscano, Miguel G ^a,b   Cejudo Guillen, Marta ^a,c   Garcia Martin, Maria L ^d   Lopez, Soledad ^a,c   Franco, Jaime M ^a,c   Quintana, Francisco J ^e   Roodveldt, Cintia ^a   Pozo, David ^a,c  

^a UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^b Amarna Therapeutics   (Netherlands)

^c UNIVERSITY OF SEVILLE   (Spain)

^d Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Amyotrophic lateral sclerosis (ALS); Drug development; Genomics; Motor neuron diseases; Neurodegeneration

Indexed keywords

MICRORNA;

AMYOTROPHIC LATERAL SCLEROSIS; EPIGENETICS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; HUMAN; METABOLOMICS; NONHUMAN; PATHOPHYSIOLOGY; PROTEOMICS; REVIEW; TRANSCRIPTOMICS; FEMALE; MALE; PERSONALIZED MEDICINE;

AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; GENOMICS; HUMANS; MALE; PRECISION MEDICINE; PROTEOMICS;

EID: 84952865082     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.11.001     Document Type: Review

References (139)

1. Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009, 4:3.
2. Dadon-Nachum M., et al. The 'dying-back' phenomenon of motor neurons in ALS. J. Mol. Neurosci. 2011, 43:470-477.
3. Ludolph A.C., et al. Amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2012, 25:530-535.
4. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001, 344:1688-1700.
5. van Blitterswijk M., et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012, 21:3776-3784.
6. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
7. Kwiatkowski T.J., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
8. Chen Y.Z., et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 2004, 74:1128-1135.
9. Wu C.H., et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012, 488:499-503.
10. Deng H.X., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
11. Kim H.J., et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013, 495:467-473.
12. Le Ber I., et al. hnRNPA2B1 and hnRNPA1 mutations are rare in patients with 'multisystem proteinopathy' and frontotemporal lobar degeneration phenotypes. Neurobiol. Aging 2014, 35:934.
13. Cirulli E.T., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015, 347:1436-1441.
14. Arai T., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006, 351:602-611.
15. Kabashi E., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40:572-574.
16. Sreedharan J., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
17. Pokrishevsky E., et al. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS ONE 2012, 7:e35050.
18. DeJesus-Hernandez M., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
19. Renton A.E., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
20. Orr H.T. FTD and ALS: genetic ties that bind. Neuron 2011, 72:189-190.
21. Donnelly C.J., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013, 80:415-428.
22. Mizielinska S., et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 2014, 345:1192-1194.
23. Kwon I., et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 2014, 345:1139-1145.
24. Mori K., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013, 339:1335-1338.
25. Koutsis G., et al. C9ORF72 hexanucleotide repeat expansions are a frequent cause of Huntington disease phenocopies in the Greek population. Neurobiol. Aging 2015, 36:547.
26. Theuns J., et al. Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease. Neurology 2014, 83:1906-1913.
27. Visscher P.M., et al. Five years of GWAS discovery. Am. J. Hum. Genet. 2012, 90:7-24.
28. Vance C., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
29. Maruyama H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-226.
30. Diekstra F.P., et al. Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS. PLoS ONE 2012, 7:e35333.
31. Iida A., et al. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum. Mol. Genet. 2011, 20:3684-3692.
32. Tetsuka S., et al. ZNF512B gene is a prognostic factor in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2013, 324:163-166.
33. Blauw H.M., et al. A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2010, 19:4091-4099.
34. Wain L.V., et al. The role of copy number variation in susceptibility to amyotrophic lateral sclerosis: genome-wide association study and comparison with published loci. PLoS ONE 2009, 4:e8175.
35. Pamphlett R., et al. Looking for differences in copy number between blood and brain in sporadic amyotrophic lateral sclerosis. Muscle Nerve 2011, 44:492-498.
36. Al-Chalabi A., et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J. Neurol. Neurosurg. Psychiatry 2010, 81:1324-1326.
37. Pamphlett R., Morahan J.M. Copy number imbalances in blood and hair in monozygotic twins discordant for amyotrophic lateral sclerosis. J. Clin. Neurosci. 2011, 18:1231-1234.
38. Chestnut B.A., et al. Epigenetic regulation of motor neuron cell death through DNA methylation. J. Neurosci. 2011, 31:16619-16636.
39. Wong M., et al. Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS. Front. Cell. Neurosci. 2013, 7:279.
40. Callaghan B., et al. The association of exposure to lead, mercury, and selenium and the development of amyotrophic lateral sclerosis and the epigenetic implications. Neurodegener. Dis. 2011, 8:1-8.
41. Figueroa-Romero C., et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS ONE 2012, 7:e52672.
42. Konsoula Z., Barile F.A. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J. Pharmacol. Toxicol. Methods 2012, 66:215-220.
43. Heath P.R., et al. Investigating cell death mechanisms in amyotrophic lateral sclerosis using transcriptomics. Front. Cell. Neurosci. 2013, 7:259.
44. Saris C.G., et al. Gene expression profile of SOD1-G93A mouse spinal cord, blood and muscle. Amyotroph. Lateral Scler. Frontotemporal Degener. 2013, 14:190-198.
45. Saris C.G., et al. Meta-analysis of gene expression profiling in amyotrophic lateral sclerosis: a comparison between transgenic mouse models and human patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 2013, 14:177-189.
46. Polymenidou M., et al. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 2012, 1462:3-15.
47. Lincecum J.M., et al. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat. Genet. 2010, 42:392-399.
48. Kirby J., et al. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 2005, 128:1686-1706.
49. Sarlette A., et al. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2008, 67:1055-1062.
50. Vargas M.R., et al. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci. 2008, 28:13574-13581.
51. Tanaka K., et al. A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PLoS ONE 2014, 9:e87728.
52. Patten S.A., et al. Fishing for causes and cures of motor neuron disorders. Dis. Models Mech. 2014, 7:799-809.
53. Casci I., Pandey U.B. A fruitful endeavor: modeling ALS in the fruit fly. Brain Res. 2015, 1607:47-74.
54. Yu Y., et al. U1 snRNP is mislocalized in ALS patient fibroblasts bearing NLS mutations in FUS and is required for motor neuron outgrowth in zebrafish. Nucleic Acids Res. 2015, 43:3208-3218.
55. Coyne A.N., et al. Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation. Hum. Mol. Genet. 2015, 24:6886-6898.
56. Shioya M., et al. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator. Neuropathol. Appl. Neurobiol. 2010, 36:320-330.
57. De Felice B., et al. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 2012, 508:35-40.
58. De Felice B., et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics 2014, 15:243-253.
59. Freischmidt A., et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain 2014, 137:2938-2950.
60. Russell A.P., et al. Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol. Dis. 2012, 49:107-117.
61. Ishtiaq M., et al. Analysis of novel NEFL mRNA targeting microRNAs in amyotrophic lateral sclerosis. PLoS ONE 2014, 9:e85653.
62. Williams A.H., et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009, 326:1549-1554.
63. Buratti E., et al. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 2010, 277:2268-2281.
64. Kawahara Y., Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3347-3352.
65. King I.N., et al. The RNA-binding protein TDP-43 selectively disrupts microRNA-1/206 incorporation into the RNA-induced silencing complex. J. Biol. Chem. 2014, 289:14263-14271.
66. Morlando M., et al. FUS stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment. EMBO J. 2012, 31:4502-4510.
67. Dini Modigliani S., et al. An ALS-associated mutation in the FUS 3'-UTR disrupts a microRNA-FUS regulatory circuitry. Nat. Commun. 2014, 5:4335.
68. Lugli G., et al. Plasma exosomal miRNAs in persons with and without Alzheimer disease: altered expression and prospects for biomarkers. PLoS ONE 2015, 10:e0139233.
69. Jin J., et al. Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin. J. Neurochem. 2012, 123:477-490.
70. Elf K., et al. Alterations in muscle proteome of patients diagnosed with amyotrophic lateral sclerosis. J. Proteomics 2014, 108:55-64.
71. Acquadro E., et al. Human SOD1-G93A specific distribution evidenced in murine brain of a transgenic model for amyotrophic lateral sclerosis by MALDI imaging mass spectrometry. J. Proteome Res. 2014, 13:1800-1809.
72. Massignan T., et al. Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochem. Biophys. Res. Commun. 2007, 353:719-725.
73. Tanaka H., et al. Apoptosis-inducing factor and cyclophilin A cotranslocate to the motor neuronal nuclei in amyotrophic lateral sclerosis model mice. CNS Neurosci. Ther. 2011, 17:294-304.
74. Nardo G., et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS ONE 2011, 6:e25545.
75. Stalekar M., et al. Proteomic analyses reveal that loss of TDP-43 affects RNA processing and intracellular transport. Neuroscience 2015, 293:157-170.
76. Gonzalez de Aguilar J.L., et al. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol. Genomics 2008, 32:207-218.
77. Zhou J.Y., et al. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J. Proteome Res. 2010, 9:5133-5141.
78. Lerman B.J., et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav. 2012, 2:563-575.
79. Edri-Brami M., et al. Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells. PLoS ONE 2012, 7:e35772.
80. Haggmark A., et al. Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2014, 1:544-553.
81. Goncalves M., et al. Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis. Clin. Chim. Acta 2015, 438:342-349.
82. Jones A.P., et al. Preliminary results of proton magnetic resonance spectroscopy in motor neurone disease (amytrophic lateral sclerosis). J. Neurol. Sci. 1995, 129:85-89.
83. Gredal O., et al. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurol. 1997, 48:878-881.
84. Cwik V.A., et al. Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 1998, 50:72-77.
85. Ikeda K., et al. Quantification of brain metabolites in ALS by localized proton magnetic spectroscopy. Neurology 1998, 50:576-577.
86. Carew J.D., et al. Magnetic resonance spectroscopy of the cervical cord in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2011, 12:185-191.
87. 1H-magnetic resonance spectroscopy and clinoco-electromyographic profile in amyotrophic lateral sclerosis. Muscle Nerve 2013, 47:61-67.
88. Carew J.D., et al. Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS. Neurology 2011, 77:1370-1375.
89. Ross B., Bluml S. Magnetic resonance spectroscopy of the human brain. Anat. Rec. 2001, 265:54-84.
90. Rozen S., et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005, 1:101-108.
91. Lawton K.A., et al. Biochemical alterations associated with ALS. Amyotroph. Lateral Scler. 2012, 13:110-118.
92. Zoccolella S., et al. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurol. 2008, 70:222-225.
93. Simone I.L., et al. Serum N-acetylaspartate level in amyotrophic lateral sclerosis. Arch. Neurol. 2011, 68:1308-1312.
94. Zoccolella S., et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J. Neurol. 2011, 258:238-243.
95. Tarasiuk J., et al. CSF markers in amyotrophic lateral sclerosis. J. Neural Transm. 2012, 119:747-757.
96. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS ONE 2010, 5:e13223.
97. Wuolikainen A., et al. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS ONE 2011, 6:e17947.
98. Wuolikainen A., et al. ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations. Mol. Gen. Metabol. 2012, 105:472-478.
99. Cistaro A., et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur. J. Nucl. Med. Mol. Imaging 2014, 41:844-852.
100. Verschueren J., et al. Impact of the C9Orf72 expansion on brain glucose metabolism in ALS patients. J. Nucl. Med. 2013, 54:155.
101. Andreassen O.A., et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. 2001, 77:383-390.
102. Derave W., et al. Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol. Dis. 2003, 13:264-272.
103. Niessen H.G., et al. Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 2007, 25:1669-1677.
104. Choi J.K., et al. Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur. J. Neurosci. 2009, 30:2143-2150.
105. Lawton K.A., et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph. Lateral Scler. Frontotemporal Degener. 2014, 15:362-370.
106. Wuolikainen A., et al. Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotroph. Lateral Scler. 2009, 10:229-236.
107. Dowling P., Clynes M. Conditioned media from cell lines: a complementary model to clinical specimens for the discovery of disease-specific biomarkers. Proteomics 2011, 11:794-804.
108. Boillee S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
109. Ilieva H., et al. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
110. Haidet-Phillips A.M., et al. Astrocytes from familial and sporadic ALSpatients are toxic to motor neurons. Nat. Biotechnol. 2011, 29:824-828.
111. Gomes C., et al. Mutant superoxide dismutase 1 overexpression in NSC-34 cells: effect of trehalose on aggregation, TDP-43 localization and levels of co-expressed glycoproteins. Neurosci. Lett. 2010, 475:145-149.
112. Urushitani M., et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 2006, 9:108-118.
113. Grad L.I., et al. Exosome-dependent and independent mechanisms are involved in prion-like transmission of propagated Cu/Zn superoxide dismutase misfolding. Prion 2014, 8:331-335.
114. McKee A.C., et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J. Neuropathol. Exp. Neurol. 2010, 69:918-929.
115. Somalinga B.R., et al. TDP-43 identified from a genome wide RNAi screen for SOD1 regulators. PLoS One 2012, 7:e35818.
116. Kabashi E., et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS genetics 2011, 7:e1002214.
117. Volkening K., et al. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res. 2009, 1305:168-182.
118. Higashi S., et al. TDP-43 physically interacts with amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase. Neurochem. Int. 2010, 57:906-913.
119. Hooten K.G., et al. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics 2015, 12:364-375.
120. Urushitani M., et al. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:2495-2500.
121. Takeuchi S., et al. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J. Neuropathol. Exp. Neurol. 2010, 69:1044-1056.
122. Rakhit R., et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat. Med. 2007, 13:754-759.
123. Liu H.N., et al. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J. Neurosci. 2012, 32:8791-8799.
124. Cheah B.C., et al. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 2010, 17:1199-1942.
125. Miller R.G., et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2007, 1:CD001447.
126. Joyce N., et al. Mesenchymal stem cells for the treatment of neurodegenerative disease. Reg. Med. 2010, 5:933-946.
127. Mazzini L., et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy 2012, 14:56-60.
128. Uccelli A., et al. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol. Med. 2012, 18:794-804.
129. Knippenberg S., et al. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS ONE 2012, 7:e36857.
130. Hong Y.H., et al. Diffusion tensor MRI as a diagnostic tool of upper motor neuron involvement in amyotrophic lateral sclerosis. J. Neurol. Sci. 2004, 227:73-78.
131. Sach M., et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 2004, 127:340-350.
132. Yin H., et al. Combined MR spectroscopic imaging and diffusion tensor MRI visualizes corticospinal tract degeneration in amyotrophic lateral sclerosis. J. Neurol. 2004, 251:1249-1254.
133. Agosta F., et al. A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J. Neurol. Neurosurg. Psychiatry 2009, 80:53-55.
134. Metwalli N.S., et al. Utility of axial and radial diffusivity from diffusion tensor MRI as markers of neurodegeneration in amyotrophic lateral sclerosis. Brain Res. 2010, 1348:156-164.
135. Turner M.R., Modo M. Advances in the application of MRI to amyotrophic lateral sclerosis. Exp. Opin. Med. Diagn. 2010, 4:483-496.
136. Valsasina P., et al. Diffusion anisotropy of the cervical cord is strictly associated with disability in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2007, 78:480-484.
137. Kim J.H., Song S.K. Diffusion tensor imaging of the mouse brainstem and cervical spinal cord. Nat. Protocol. 2013, 8:409-417.
138. Cosottini M., et al. Evaluation of corticospinal tract impairment in the brain of patients with amyotrophic lateral sclerosis by using diffusion tensor imaging acquisition schemes with different numbers of diffusion-weighting directions. J. Comp. Assist. Tomography 2010, 34:746-750.
139. Ignjatovic A., et al. Brain iron MRI: a biomarker for amyotrophic lateral sclerosis. J. Magn. Res. Imaging 2013, 38:1472-1479.